
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4524453/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. Arthritis Care and Research, 2022, 74, 1013-1018.	3.4	4
2	Response to: â€~Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues' by Ghajari and Sabour. Annals of the Rheumatic Diseases, 2022, 81, e106-e106.	0.9	2
3	The role of neutrophils in rheumatic disease-associated vascular inflammation. Nature Reviews Rheumatology, 2022, 18, 158-170.	8.0	32
4	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 386-392.	5.6	50
5	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 393-399.	5.6	71
6	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis and Rheumatology, 2022, 74, 400-406.	5.6	62
7	P115 Remote clinical management: incorporating electronic assessment of patients with rheumatic diseases into standard clinical pathways and comparison to in-person assessment. Rheumatology, 2022, 61, .	1.9	1
8	Pulmonary involvement in primary systemic vasculitides. Rheumatology, 2021, 61, 319-330.	1.9	16
9	P211â€ f Aortitis: clinical experience within a tertiary centre. Rheumatology, 2021, 60, .	1.9	0
10	P203 Incidence, characteristics and determinants of severe infections in patients with anti-neutrophil cytoplasm antibody-associated vasculitis receiving rituximab therapy: a single centre study. Rheumatology, 2021, 60, .	1.9	0
11	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. Annals of the Rheumatic Diseases, 2021, 80, 1475-1482.	0.9	34
12	Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVIDâ€19: A Binational, Registryâ€Based Cohort Study. Arthritis and Rheumatology, 2021, 73, 1713-1719.	5.6	35
13	Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 2021, 60, 617-628.	1.9	22
14	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. Rheumatology, 2021, 60, 4361-4366.	1.9	15
15	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.9	667
16	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care and Research, 2020, 72, 1615-1624.	3.4	77
17	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. Arthritis and Rheumatology, 2020, 72, 667-676.	5.6	33
18	Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. Rheumatology, 2020, 59, 2316-2324.	1.9	34

#	Article	IF	CITATIONS
19	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. Rheumatology, 2020, 59, 2299-2307.	1.9	21
20	Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Annals of the Rheumatic Diseases, 2020, 79, 393-399.	0.9	77
21	EPO3 An audit of glucocorticoid prescription in patients with giant cell arteritis. Rheumatology, 2020, 59, .	1.9	0
22	A hidden lung cancer in a patient with granulomatosis with polyangiitis. BJR case Reports, 2020, 6, 20190114.	0.2	2
23	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. Rheumatology, 2020, 59, 3717-3726.	1.9	26
24	Comment on: Diagnosis of giant cell arteritis: reply. Rheumatology, 2020, 59, e119-e121.	1.9	0
25	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. Rheumatology and Therapy, 2020, 7, 793-810.	2.3	30
26	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 1243-1249.	0.9	93
27	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56
28	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
29	Diagnosis of giant cell arteritis. Rheumatology, 2020, 59, iii5-iii16.	1.9	58
30	ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies. JCI Insight, 2020, 5, .	5.0	53
31	Early development of new cardiovascular risk factors in the systemic vasculitides. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 126-134.	0.8	2
32	Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis. Autoimmunity Reviews, 2019, 18, 102405.	5.8	19
33	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	5.6	82
34	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	2.0	6
35	FRIO284â€RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
36	THU0286â€MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 202 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .	18	2

#	Article	IF	CITATIONS
37	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open, 2019, 5, e001003.	3.8	52
38	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open, 2019, 5, e001020.	3.8	56
39	Small- and Medium-Vessel Primary Vasculitis. , 2019, , 789-807.e1.		0
40	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212713.	0.9	38
41	The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Rheumatology, 2018, 57, 227-235.	1.9	101
42	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
43	i128 Improving value projects. Rheumatology, 2018, 57, .	1.9	0
44	Preface. Best Practice and Research in Clinical Rheumatology, 2018, 32, 1-2.	3.3	1
45	035â€fAortic dissection secondary to giant cell arteritis in a patient on tocilizumab for established seronegative rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	1
46	Clinical features and structured clinical evaluation of vasculitis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 31-51.	3.3	31
47	Making the most of the waiting room: Electronic patient engagement, a mixed methods study. Digital Health, 2018, 4, 205520761775130.	1.8	3
48	050 IgG4 related disease causing left anterior descending artery stenosis successfully treated with rituximab therapy. Rheumatology, 2018, 57, .	1.9	1
49	The use of ultrasound in the management of large-vessel vasculitis: an evolving concept. Clinical and Experimental Rheumatology, 2018, 36 Suppl 114, 96-102.	0.8	1
50	Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?. RMD Open, 2017, 3, e000353.	3.8	12
51	The RUDY study: using digital technologies to enable a research partnership. European Journal of Human Genetics, 2017, 25, 816-822.	2.8	39
52	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	27.0	682
53	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23

Polyarteritis Nodosa and Related Disorders. , 2017, , 1559-1570.

#	Article	IF	CITATIONS
55	333.â€∱THE ROLE OF ULTRASOUND IN THE MANAGEMENT OF GIANT CELL ARTERITIS IN ROUTINE CLINICAL PRACTICE. Rheumatology, 2017, 56, .	1.9	о
56	Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined) Tj ETQq0 0 0	rgBT /Ove	erlock 10 Tf 50

57	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.9	940
58	Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. Journal of Rheumatology, 2016, 43, 1085-1092.	2.0	24
59	Cryofibrinogenaemia—a neglected disease. Rheumatology, 2016, 56, kew379.	1.9	8
60	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technology Assessment, 2016, 20, 1-238.	2.8	313
61	Giant cell arteritis: Current treatment and management. World Journal of Clinical Cases, 2015, 3, 484.	0.8	50
62	O18. Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis. Rheumatology, 2015, , .	1.9	0
63	Disease assessment in systemic vasculitis. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i76-82.	0.7	8
64	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases, 2015, 74, 1178-1182.	0.9	217
65	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology, 2015, 54, 471-481.	1.9	104
66	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Annals of the Rheumatic Diseases, 2015, 74, 177-184.	0.9	214
67	Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: AÂNICE Single Technology Appraisal. Pharmacoeconomics, 2014, 32, 1171-1183.	3.3	12
68	State of the Art in the Treatment of Systemic Vasculitides. Frontiers in Immunology, 2014, 5, 471.	4.8	24
69	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology, 2014, 53, 2306-2309.	1.9	246
70	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology, 2014, 53, 953-956.	1.9	38
71	Current Status of Outcome Measure Development in Vasculitis. Journal of Rheumatology, 2014, 41, 593-598.	2.0	31
72	Explaining fatigue in ANCA-associated vasculitis. Rheumatology, 2013, 52, 1680-1685.	1.9	50

#	Article	IF	CITATIONS
73	Maintenance of clinical remission in ANCA-associated vasculitis. Nature Reviews Rheumatology, 2013, 9, 127-132.	8.0	17
74	2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and Rheumatism, 2013, 65, 1-11.	6.7	4,839
75	Update on the classification of vasculitis. Best Practice and Research in Clinical Rheumatology, 2013, 27, 3-17.	3.3	34
76	Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update. British Journal of General Practice, 2013, 63, 553-554.	1.4	7
77	Polyarteritis Nodosa and Related Disorders. , 2013, , 1498-1507.		1
78	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2012, 71, 484-492.	0.9	451
79	Large vessel vasculitides. Current Opinion in Cardiology, 2012, 27, 578-584.	1.8	15
80	Diagnosis and management of ANCA associated vasculitis. BMJ: British Medical Journal, 2012, 344, e26-e26.	2.3	100
81	Patient-reported Outcomes in Polymyalgia Rheumatica. Journal of Rheumatology, 2012, 39, 795-803.	2.0	64
82	Damage Assessment in ANCA-Associated Vasculitis. Current Rheumatology Reports, 2012, 14, 494-500.	4.7	42
83	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology, 2012, 51, 634-643.	1.9	102
84	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the Rheumatic Diseases, 2012, 71, 955-960.	0.9	348
85	Recurrent inflammatory stenosis of the M1 segment: diagnostic and therapeutic considerations. Neuroradiology, 2012, 54, 529-532.	2.2	0
86	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
87	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 344-353.	6.4	182
88	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clinical and Experimental Rheumatology, 2012, 30, S162-8.	0.8	13
89	Systemic vasculitisis it time to reclassify?. Rheumatology, 2011, 50, 643-645.	1.9	41
90	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2011, 70, 704-704.	0.9	106

#	Article	IF	CITATIONS
91	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.9	47
92	Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 488-494.	0.9	719
93	Pulmonary-renal syndromes: An update for respiratory physicians. Respiratory Medicine, 2011, 105, 1413-1421.	2.9	34
94	The Need for Diagnostic Criteria in Systemic Vasculitis. Current Immunology Reviews, 2011, 7, 394-401.	1.2	0
95	Nomenclature and classification of vasculitis – update on the ACR/EULAR Diagnosis and Classification of Vasculitis Study (DCVAS). Clinical and Experimental Immunology, 2011, 164, 11-13.	2.6	76
96	Long-term damage to the ENT system in Wegener's granulomatosis. European Archives of Oto-Rhino-Laryngology, 2011, 268, 733-739.	1.6	17
97	Time to focus on outcome assessment tools for childhood vasculitis. Pediatric Rheumatology, 2011, 9, 29.	2.1	4
98	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care and Research, 2011, 63, 588-596.	3.4	147
99	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care and Research, 2011, 63, 1055-1061.	3.4	63
100	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. Arthritis and Rheumatism, 2011, 63, 863-864.	6.7	244
101	Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology, 2011, 50, 2214-2222.	1.9	91
102	Granulomatosis with Polyangiitis (Wegener's). Journal of the American Society of Nephrology: JASN, 2011, 22, 587-588.	6.1	49
103	BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology, 2011, 50, 2311-2313.	1.9	42
104	Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology, 2011, 50, 697-702.	1.9	69
105	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology, 2011, 50, 899-905.	1.9	89
106	An approach to the diagnosis and management of systemic vasculitis. Clinical and Experimental Immunology, 2010, 160, 143-160.	2.6	38
107	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology, 2010, 49, 1197-1199.	1.9	49
108	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology, 2010, 49, 2217-2219.	1.9	187

#	Article	IF	CITATIONS
109	Outcome Measures in ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America, 2010, 36, 587-607.	1.9	12
110	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	27.0	1,471
111	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
112	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology, 2010, , .	1.9	1
113	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. Journal of Rheumatology, 2009, 36, 2362-2368.	2.0	35
114	Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2009, 68, 1125-1130.	0.9	72
115	Pharmacotherapy of vasculitis. Expert Opinion on Pharmacotherapy, 2009, 10, 1273-1289.	1.8	12
116	Assessment of damage in vasculitis: expert ratings of damage. Rheumatology, 2009, 48, 823-827.	1.9	34
117	Cardiovascular involvement in primary systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 419-428.	3.3	24
118	Pleural Wegener's granulomatosis: a rare presentation. Histopathology, 2009, 54, 391-393.	2.9	3
119	Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases, 2009, 68, 1827-1832.	0.9	825
120	Developing multidisciplinary guidelines for the management of early rheumatoid arthritis. Musculoskeletal Care, 2008, 6, 97-107.	1.4	17
121	Assessment of systemic vasculitis. Autoimmunity Reviews, 2008, 8, 170-175.	5.8	13
122	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases, 2008, 67, 1004-1010.	0.9	343
123	Development of comprehensive disease assessment in systemic vasculitis. Postgraduate Medical Journal, 2008, 84, 143-152.	1.8	91
124	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 569-570.	0.9	2
125	Update on the use of biologics in primary systemic vasculitides. Expert Review of Clinical Immunology, 2007, 3, 901-911.	3.0	0
126	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.9	524

#	Article	IF	CITATIONS
127	Outpatient assessment of systemic vasculitis. Best Practice and Research in Clinical Rheumatology, 2007, 21, 713-732.	3.3	23
128	Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward?. Annals of Internal Medicine, 2007, 146, 674.	3.9	14
129	Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). Rheumatology, 2006, 45, 649-652.	1.9	28
130	The role of biologic therapies in the management of systemic vasculitis. Autoimmunity Reviews, 2006, 5, 273-278.	5.8	19
131	How to diagnose and treat secondary forms of vasculitis. Best Practice and Research in Clinical Rheumatology, 2005, 19, 321-336.	3.3	27
132	Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis and Rheumatism, 2005, 52, 2461-2469.	6.7	723
133	Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?. Annals of the Rheumatic Diseases, 2005, 65, 841-844.	0.9	20
134	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	2.0	32
135	Disease assessment in systemic vasculitis. APLAR Journal of Rheumatology, 2004, 7, 150-157.	0.2	0
136	Assessing disease activity in the systemic vasculitides. Current Opinion in Rheumatology, 2002, 14, 23-28.	4.3	22
137	Maternal Stressors, Maternal Wellbeing and Children's Wellbeing in the Context of Juvenile Idiopathic Arthritis. Early Child Development and Care, 2002, 172, 89-98.	1.3	27
138	Measuring disease activity and outcomes in clinical studies Cleveland Clinic Journal of Medicine, 2002, 69, SII100-SII100.	1.3	2
139	Evaluation of vasculitis disease activity in Europe. European Journal of Internal Medicine, 2001, 12, 401-402.	2.2	8
140	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism, 2001, 44, 912-920.	6.7	400
141	Introduction to, and classification of, the systemic vasculitides. Best Practice and Research in Clinical Rheumatology, 2001, 15, 187-202.	3.3	18
142	The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 615-621.	0.5	61
143	Medical student appraisal of interactive computer-assisted learning programs embedded in a general pathology course. Journal of Pathology, 2000, 191, 462-465.	4.5	18
144	Pseudoporphyria and Nonsteroidal Antiinflammatory Agents in Children with Juvenile Idiopathicâ€∫Arthritis. Pediatric Dermatology, 2000, 17, 480-483.	0.9	41

#	Article	IF	CITATIONS
145	Is it possible to offer evidence-based treatment for systemic vasculitis?: Editorial review. Scandinavian Journal of Rheumatology, 2000, 29, 211-215.	1.1	7
146	Medical student appraisal of interactive computerâ€assisted learning programs embedded in a general pathology course. Journal of Pathology, 2000, 191, 462-465.	4.5	1
147	Optimisation of Cyclophosphamide Therapy in Systemic Vasculitis. Clinical Pharmacokinetics, 1998, 34, 79-90.	3.5	16
148	Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Rheumatology, 1998, 37, 57-63.	1.9	89
149	Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 401-409.	0.5	199
150	Damage occurs early in systemic vasculitis and is an index of outcome. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 391-399.	0.5	104
151	10 Disease assessment and management of the vasculitides. Bailliere's Clinical Rheumatology, 1997, 11, 423-446.	1.0	97
152	Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis and Rheumatism, 1997, 40, 371-380.	6.7	497
153	Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease. Drugs, 1994, 47, 259-285.	10.9	7
154	CORRELATION OF BLOOD LEVELS OF SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND VASCULITIS. Rheumatology, 1994, 33, 1112-1116.	1.9	78
155	Treatment of vasculitis in rheumatoid arthritis. Annales De Médecine Interne, 1994, 145, 566-76.	0.2	1
156	Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM - Monthly Journal of the Association of Physicians, 1994, 87, 671-8.	0.5	611
157	Classical versus non-renal Wegener's granulomatosis. The Quarterly Journal of Medicine, 1994, 87, 161-7.	1.0	43
158	Relapses in patients with a systemic vasculitis. The Quarterly Journal of Medicine, 1993, 86, 779-89.	1.0	77